Bellevue Life Sciences Acquisition Corp. Files 8-K

TL;DR

BLAC filed an 8-K on Jan 23, 2025, reporting a material definitive agreement and financial obligations.

AI Summary

Bellevue Life Sciences Acquisition Corp. (BLAC) filed an 8-K on January 23, 2025, reporting the entry into a material definitive agreement. The filing also details the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Specific details regarding the agreement, financial obligations, and exhibits were included in the filing.

Why It Matters

This filing indicates a significant development for Bellevue Life Sciences Acquisition Corp., potentially involving new financial commitments or strategic agreements that could impact its future operations and shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and financial obligations, which could introduce new risks or opportunities for the company.

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Filer of the 8-K report
• 0001840425 (company) — Central Index Key for Bellevue Life Sciences Acquisition Corp.
• January 23, 2025 (date) — Date of the earliest event reported in the 8-K

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $1,200,000 — , 2024, in the principal amounts of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv)
• $50,000 — incipal amounts of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv) $300,000, res
• $140,000 — of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv) $300,000, respectively. As p
• $300,000 — (ii) $50,000, (iii) $140,000, and (iv) $300,000, respectively. As previously disclosed

Filing Documents

• ea0228426-8k_bellevue.htm (8-K) — 40KB
• ea022842601ex10-1_bellevue.htm (EX-10.1) — 12KB
• 0001213900-25-005957.txt ( ) — 285KB
• blac-20250123.xsd (EX-101.SCH) — 4KB
• blac-20250123_def.xml (EX-101.DEF) — 27KB
• blac-20250123_lab.xml (EX-101.LAB) — 38KB
• blac-20250123_pre.xml (EX-101.PRE) — 26KB
• ea0228426-8k_bellevue_htm.xml (XML) — 8KB

01. Entry into

Item 1.01. Entry into a Material Definitive Agreement. The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

03. Creation of a Direct Financial Obligation or an Obligation

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Promissory Note Amendments As previously disclosed by Bellevue Life Sciences Acquisition Corp. (the " Company ") in its Current Reports on Form 8-K filed with the Securities and Exchange Commission on (i) April 11, 2024, (ii) April 22, 2024, (iii) May 14, 2024, and (iv) July 16, 2024, the Company issued unsecured promissory notes (each, a " Promissory Note " and, collectively, the " Promissory Notes ") to Bellevue Global Life Sciences Investors, LLC, the Company's sponsor (" Sponsor "), on (i) April 8, 2024, (ii) April 17, 2024, (iii) May 14, 2024, and (iv) July 11, 2024, in the principal amounts of (i) $1,200,000, (ii) $50,000, (iii) $140,000, and (iv) $300,000, respectively. As previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities Exchange Commission on January 10, 2025, on January 9, 2025, the Company and Sponsor entered into an amendment to extend the maturity date of each Promissory Note to the earlier of (i) September 30, 2025 and (ii) the date on which the Company consummates an initial business combination. On January 23, 2025, the Company and Sponsor entered into a second amendment to amend the maturity date of each Promissory Note to provide that each Promissory Note matures on September 30, 2025, irrespective of whether the Company consummates an initial business combination prior to September 30, 2025. No other terms of the Promissory Notes were amended. The foregoing description of the Promissory Notes Amendment is qualified in its entirety by reference to the full text of the Promissory Notes Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Second Amendment to Promissory Notes, dated January 23, 2025, between Bellevue Life Sciences Acquisition Corp. and Bellevue Global Life Sciences Investors, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 23, 2025 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR